IRIS
GHIA, PAOLO PROSPERO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 8.874
AS - Asia 8.812
NA - Nord America 6.181
SA - Sud America 2.546
AF - Africa 195
OC - Oceania 23
Continente sconosciuto - Info sul continente non disponibili 5
Totale 26.636
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.921
RU - Federazione Russa 4.835
SG - Singapore 3.215
CN - Cina 2.677
BR - Brasile 2.086
HK - Hong Kong 1.385
IT - Italia 1.225
SE - Svezia 1.038
VN - Vietnam 828
FR - Francia 471
DE - Germania 369
AR - Argentina 197
GB - Regno Unito 176
FI - Finlandia 163
IN - India 149
NL - Olanda 131
AT - Austria 118
MX - Messico 106
CA - Canada 99
EC - Ecuador 93
BD - Bangladesh 87
IE - Irlanda 73
ZA - Sudafrica 67
PL - Polonia 66
ID - Indonesia 61
IQ - Iraq 61
JP - Giappone 46
TR - Turchia 46
CO - Colombia 42
ES - Italia 42
PK - Pakistan 41
PY - Paraguay 40
MA - Marocco 31
UA - Ucraina 29
AE - Emirati Arabi Uniti 28
VE - Venezuela 28
KE - Kenya 23
SA - Arabia Saudita 23
CL - Cile 22
AU - Australia 20
CH - Svizzera 20
EG - Egitto 20
LT - Lituania 20
UZ - Uzbekistan 20
PE - Perù 19
TN - Tunisia 17
AZ - Azerbaigian 14
DK - Danimarca 13
MY - Malesia 13
IL - Israele 12
BE - Belgio 11
PH - Filippine 11
BO - Bolivia 10
KZ - Kazakistan 10
DZ - Algeria 9
IR - Iran 9
UY - Uruguay 9
CR - Costa Rica 8
PT - Portogallo 8
AL - Albania 7
DO - Repubblica Dominicana 7
GR - Grecia 7
JM - Giamaica 7
JO - Giordania 7
KR - Corea 7
NP - Nepal 7
PA - Panama 7
TW - Taiwan 7
BH - Bahrain 6
HU - Ungheria 6
KW - Kuwait 6
TH - Thailandia 6
AO - Angola 5
BG - Bulgaria 5
HN - Honduras 5
NO - Norvegia 5
OM - Oman 5
RS - Serbia 5
BB - Barbados 4
BY - Bielorussia 4
CZ - Repubblica Ceca 4
ET - Etiopia 4
LB - Libano 4
LU - Lussemburgo 4
MV - Maldive 4
SN - Senegal 4
SV - El Salvador 4
TT - Trinidad e Tobago 4
GA - Gabon 3
LV - Lettonia 3
MD - Moldavia 3
NI - Nicaragua 3
PS - Palestinian Territory 3
SK - Slovacchia (Repubblica Slovacca) 3
XK - ???statistics.table.value.countryCode.XK??? 3
AM - Armenia 2
BN - Brunei Darussalam 2
BS - Bahamas 2
BW - Botswana 2
CY - Cipro 2
Totale 26.599
Salva come PNG Salva come JPEG
Città #
Dallas 2.075
Singapore 1.411
Hong Kong 1.377
Moscow 1.154
Ashburn 767
San Jose 609
Shanghai 486
Hefei 435
Lauterbourg 382
Lawrence 328
Princeton 328
Milan 319
Ho Chi Minh City 302
Beijing 263
New York 183
Hanoi 176
São Paulo 169
Nuremberg 143
Los Angeles 124
Rome 124
Helsinki 89
Munich 75
Dublin 72
Boardman 65
Rio de Janeiro 55
Warsaw 55
Guangzhou 51
Orem 51
Santa Clara 51
Vienna 50
Council Bluffs 49
Brasília 42
Brooklyn 42
Tokyo 41
Belo Horizonte 39
Da Nang 39
Houston 39
Chennai 37
Johannesburg 37
Lappeenranta 36
The Dalles 35
Curitiba 34
Turku 34
Guayaquil 33
Montreal 33
Denver 32
Hangzhou 32
London 32
Naples 31
Mexico City 30
Xi'an 30
Haiphong 29
Porto Alegre 29
Frankfurt am Main 28
Poplar 28
Stockholm 28
Palermo 26
Atlanta 25
Chicago 25
Columbus 25
Quito 25
Seattle 23
Tianjin 23
Amsterdam 22
Nairobi 22
Dubai 21
Manchester 21
Shenzhen 21
Baghdad 20
Boston 20
Ribeirão Preto 20
Ridgewood 20
Salvador 20
Hải Dương 19
Mumbai 19
Tashkent 19
Thái Bình 19
Campinas 18
Manaus 18
Bari 17
Phoenix 17
Pune 17
Turin 17
Ankara 16
Guarulhos 16
Toronto 16
Jakarta 15
Querétaro 15
San Francisco 15
Santiago 15
Santo André 15
Asunción 14
Biên Hòa 14
Cesano Boscone 14
Florence 14
Florianópolis 14
Baku 13
Buenos Aires 13
Cairo 13
Dhaka 13
Totale 13.472
Salva come PNG Salva come JPEG
Nome #
Rugarli. Medicina interna sistematica 659
Venetoclax-based regimens in octogenarian patients with CLL: efficacy, safety, and comparison to BTKi in a multicenter cohort 424
Bcor loss promotes Richter transformation of chronic lymphocytic leukemia associated with Notch1 activation in mice: Lymphoma 419
ATM aberrations in chronic lymphocytic leukemia: del(11q) rather than ATM mutations is an adverse-prognostic biomarker: CHRONIC LYMPHOCYTIC LEUKEMIA 408
3D-culture of CLL cells in bioreactor identifies the bone marrow as a key regulator of HS1 function in response to Ibrutinib 205
Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321) 195
A retinoic acid-dependent stroma-leukemia crosstalk promotes chronic lymphocytic leukemia progression 142
3D co-culture model of chronic lymphocytic leukemia bone marrow microenvironment predicts patient-specific response to mobilizing agents 138
Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial 131
Chronic lymphocytic leukaemia 129
A novel Rag2(-/-)gamma(-/-)(c)-xenograft model of human CLL 122
3D Bioprinting Allows the Establishment of Long-Term 3D Culture Model for Chronic Lymphocytic Leukemia Cells 112
ZAP-70 is expressed by normal and malignant human B-cell subsets of different maturational stage 111
A screening study of Chlamydia psittaci infection in 172 cases of nodal and extranodal non-hodgkin lymphomas 109
Iron Induces Cell Death and Strengthens the Efficacy of Antiandrogen Therapy in Prostate Cancer Models 108
Additional booster doses in patients with chronic lymphocytic leukemia induce humoral and cellular immune responses to SARS-CoV-2 similar to natural infection regardless ongoing treatments: A study by ERIC, the European Research Initiative on CLL 106
A novel ex vivo high-throughput assay reveals antiproliferative effects of idelalisib and ibrutinib in chronic lymphocytic leukemia 106
Lack of TIR8/SIGIRR triggers progression of chronic lymphocytic leukemia in mouse models 103
A complementary role of multiparameter flow-cytometry and high-throughput sequencing for minimal residual disease (MRD) detection in chronic lymphocytic leukemia (CLL): An european research initiative on CLL (ERIC) study 103
A new life for rituximab? 103
A woman and her canary: a tale of chlamydiae and lymphomas 102
Pathogen-specific B-cell receptors drive chronic lymphocytic leukemia by light-chain-dependent cross-reaction with autoantigens 102
Supplementary Data from Iron Induces Cell Death and Strengthens the Efficacy of Antiandrogen Therapy in Prostate Cancer Models 101
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia 101
Inhibition of chronic lymphocytic leukemia progression by full-length chromogranin A and its N-terminal fragment in mouse models 101
A novel molecular complex expressed on immature B cells: A possible role in T cell-independent B cell development 100
ABVD CAN BE SAFELY ADMINISTERED REGARDLESS OF ABSOLUTE NEUTROPHIL COUNT AND WITHOUT G-CSF SUPPORT IN HODGKIN'S LYMPHOMA PATIENTS 100
Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia 100
Targeting the LYN/HS1 signaling axis in chronic lymphocytic leukemia 97
A different ontogenesis for chronic lymphocytic leukemia cases carrying stereotyped antigen receptors: molecular and computational evidence 97
The evolving landscape of COVID-19 and post-COVID condition in patients with chronic lymphocytic leukemia: A study by ERIC, the European research initiative on CLL 95
A frequent EcoRI polymorphism in the bcl-2 gene 94
A look into the future: can minimal residual disease guide therapy and predict prognosis in chronic lymphocytic leukemia? 94
COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study 94
Longitudinal analysis of T cell receptor repertoires reveals shared patterns of antigen-specific response to SARS-CoV-2 infection 93
IκBε deficiency accelerates disease development in chronic lymphocytic leukemia 93
In Vitro Sensitivity of CLL Cells to Fludarabine May Be Modulated by the Stimulation of Toll-like Receptors 93
Disrupting pro-survival and inflammatory pathways with dimethyl fumarate sensitizes chronic lymphocytic leukemia to cell death 91
CLL-461 Humoral Response to COVID-19 Vaccine: A Challenge in CLL 90
General population low-count CLL-like MBL persists over time without clinical progression, although carrying the same cytogenetic abnormalities of CLL. 90
CD4+T cells sustain aggressive chronic lymphocytic leukemia in Em- TCL1 mice through a CD40L-independent mechanism 90
BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinib 89
EZN-2208 treatment suppresses chronic lymphocytic leukaemia by interfering with environmental protection and increases response to fludarabine 89
ZAP-70 expression is associated with increased risk of autoimmune cytopenias in CLL patients 89
Navigating the changing landscape of BTK-targeted therapies for B cell lymphomas and chronic lymphocytic leukaemia 87
In vitro and in vivo model of a novel immunotherapy approach for chronic lymphocytic leukemia by anti-CD23 chimeric antigen receptor 87
HIF-1α regulates the interaction of chronic lymphocytic leukemia cells with the tumor microenvironment 87
A single-tube multiplex method for monitoring mutations in cysteine 481 of Bruton Tyrosine Kinase (BTK) gene in chronic lymphocytic leukemia patients treated with ibrutinib 87
A spheroid model that recapitulates the protective role of the lymph node microenvironment and serves as a platform for drug testing in chronic lymphocytic leukemia 86
Targeting B-cell anergy in chronic lymphocytic leukemia. 86
Monoclonal B-cell lymphocytosis: right track or red herring? 86
Assessing Patients' Knowledge on Chronic Lymphocytic Leukemia: Validation of the ERIC CLL Knowledge Questionnaire in Greece 86
Acalabrutinib-based regimens in frontline or relapsed/refractory higher-risk CLL: Pooled analysis of 5 clinical trials 85
Bone Marrow Histopathology in the Diagnostic Evaluation of Splenic Marginal-zone and Splenic Diffuse Red Pulp Small B-cell Lymphoma: A Reliable Substitute for Spleen Histopathology? 85
Lenalidomide enhances CD23.CAR T cell therapy in chronic lymphocytic leukemia 85
Chronic lymphocytic leukemia 84
Are we finally getting personal? Moving towards a personalized approach in chronic lymphocytic leukemia 84
T cell receptor gene repertoire profiles in subgroups of patients with chronic lymphocytic leukemia bearing distinct genomic aberrations 83
Xenograft models of chronic lymphocytic leukemia: problems, pitfalls and future directions. 83
Ibrutinib (Ibr) Plus Venetoclax (Ven) for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Results from the MRD Cohort of the Phase 2 CAPTIVATE Study 83
Invariant NKT cells contribute to chronic lymphocytic leukemia surveillance and prognosis 83
Obinutuzumab plus chlorambucil versus ibrutinib in previously untreated chronic lymphocytic leukemia patients without TP53 disruptions: A real-life CLL campus study 81
Acalabrutinib in High-Risk Chronic Lymphocytic Leukaemia Naïve Patients: An Italian Multicenter Retrospective Observational Real-Life Experience 81
B-Cell Clones as Early Markers for Chronic Lymphocytic Leukemia 81
PYK2 is overexpressed in chronic lymphocytic leukaemia: A potential new therapeutic target 80
Distinct Innate Immunity Pathways to Activation and Tolerance in Subgroups of Chronic Lymphocytic Leukemia with Distinct Immunoglobulin Receptors. 80
[Cellular and molecular mechanisms conditioning the accumulation of resting neoplastic cells in B-lymphocyte chronic lymphatic leukemia] 79
Iron causes lipid oxidation and inhibits proteasome function in multiple myeloma cells: A proof of concept for novel combination therapies 78
Chronic Lymphocytic Leukemia with Mutated IGHV4-34 Receptors: Shared and Distinct Immunogenetic Features and Clinical Outcomes 77
Interleukin-1 receptor-associated kinase 4 inhibitor interrupts toll-like receptor signalling and sensitizes chronic lymphocytic leukaemia cells to apoptosis 77
Functional differences between IgM and IgD signaling in chronic lymphocytic leukemia 76
Toll-like receptor signaling pathway in chronic lymphocytic leukemia: distinct gene expression profiles of potential pathogenic significance in specific subsets of patients 75
TP53 aberrations in chronic lymphocytic leukemia: An overview of the clinical implications of improved diagnostics 75
Genomic Profiling for Clinical Decision Making in Lymphoid Neoplasms 74
Anti-CD20 rechallenge with ofatumumab in relapsed/refractory splenic marginal zone lymphoma: the MORE trial 74
Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and severe COVID-19: a study of ERIC, the European Research Initiative on CLL 74
Over 30% of patients with splenic marginal zone lymphoma express the same immunoglobulin heavy variable gene: ontogenetic implications 74
Olaptesed pegol (NOX-A12) with bendamustine and rituximab: a phase IIa study in patients with relapsed/refractory chronic lymphocytic leukemia 74
CLL-like monoclonal B-cell lymphocytosis: are we all bound to have it? 72
COVID-19 and Chronic Lymphocytic Leukemia: Where We Stand Now 71
MINIMAL RESIDUAL DISEASE-DRIVEN TREATMENT INTENSIFICATION WITH SEQUENTIAL ADDITION OF IBRUTINIB TO VENETOCLAX IN R/R CLL 71
In vitro growth of human multiple myeloma: implications for biology and therapy 71
Clinical effect of stereotyped B-cell receptor immunoglobulins in chronic lymphocytic leukaemia: a retrospective multicentre study 71
Zanubrutinib monotherapy for patients with treatment naïve chronic lymphocytic leukemia and 17p deletion 71
Protocol for generation of 3D bone marrow surrogate microenvironments in a rotary cell culture system 71
Characterization of zanubrutinib safety and tolerability profile and comparison with ibrutinib safety profile in patients with B-cell malignancies: post hoc analysis of a large clinical trial safety database 70
A matching-adjusted indirect comparison of acalabrutinib versus zanubrutinib in relapsed or refractory chronic lymphocytic leukemia 70
Monoclonal B lymphocytosis in the general population 70
The functional in vitro response to CD40 ligation reflects a different clinical outcome in patients with chronic lymphocytic leukemia. 70
Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results 70
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee 69
Monoclonal B-cell lymphocytosis, monoclonal gammopathy of undetermined significance, and T-cell clones of uncertain significance: are these premalignant conditions sharing a common identity? 69
Correction: Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY 69
Ordering of human bone marrow B lymphocyte precursors by single-cell polymerase chain reaction analyses of the rearrangement status of the immunoglobulin H and L chain gene loci 69
Acalabrutinib monotherapy for treatment of chronic lymphocytic leukaemia (ACE-CL-001): analysis of the Richter transformation cohort of an open-label, single-arm, phase 1–2 study 69
Spontaneous regression in chronic lymphocytic leukaemia. Clinical features of 50 cases from the ERIC registry and review of the literature 68
Zanubrutinib Versus Bendamustine and Rituximab in Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Median 5-Year Follow-Up of SEQUOIA 68
Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY 67
B-cell receptor pathway mutations are infrequent in patients with chronic lymphocytic leukemia on continuous ibrutinib therapy 67
Reprogramming cell death: BCL2 family inhibition in hematological malignancies 67
Totale 10.505
Salva come PNG Salva come JPEG
Categoria #
all - tutte 160.333
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 160.333
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022193 0 0 0 79 28 6 17 17 16 9 6 15
2022/20231.988 758 410 124 3 39 254 71 111 85 32 34 67
2023/2024903 42 58 49 182 68 127 22 59 4 27 87 178
2024/20255.807 694 112 102 154 141 433 620 465 1.211 952 426 497
2025/202618.011 1.329 1.973 2.178 2.690 1.196 513 1.625 1.268 4.495 744 0 0
Totale 27.160